www.fdanews.com/articles/84543-qlt-has-setback
QLT HAS SETBACK
February 14, 2006
QLT Inc. disclosed Tuesday that a Phase 2 trial of its lemuteporfin injectable therapy in patients with benign prostatic hyperplasia "did not meet the study's primary efficacy objective at three months." The Vancouver pharmaceutical company said there was no significant difference between patients receiving the treatment and control groups.
The Globe and Mail (http://www.theglobeandmail.com/servlet/story/RTGAM.20060214.wqlt0214/BNStory/Business/home)